Feedback
Hereditary Cancer Panel, Sequencing and Deletion/Duplication
2012032
Ordering Recommendation

Confirm diagnosis of a hereditary cancer syndrome with personal or family history consistent with features of more than one cancer syndrome. When a relative has a previously identified pathogenic variant, see Familial Mutation, Targeted Sequencing (2001961).

Mnemonic
CANCERPAN
Methodology
Massively Parallel Sequencing/Exonic Oligonucleotide-based CGH Microarray
Performed
Varies
Reported
3-6 weeks
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Specimen Required
Patient Preparation
 
Collect
Lavender (EDTA) or yellow (ACD Solution A or B). 
Specimen Preparation
Transport 3 mL whole blood. (Min: 1 mL) 
Storage/Transport Temperature
Refrigerated 
Unacceptable Conditions
 
Remarks
 
Stability
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable 
Reference Interval
By report
Interpretive Data
Refer to report

Compliance Statement C: For human genetic inheritable conditions and mutations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Note
GENES TESTED: ALK, APC, ATM, ATR, AXIN2**, BAP1, BARD1, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN1B, CDKN2A, CHEK2*, DICER1, EPCAM****, FH, FLCN, MAX, MEN1, MET, MLH1, MRE11, MSH2, MSH3**, MSH6, MUTYH, NBN, NF1**, NF2, NTHL1, PALB2, PHOX2B, PMS2, POLD1, POLE, PTEN, RAD51C, RAD51D, RB1, RECQL***, RET, SDHAF2, SDHB, SDHC*, SDHD*, SMAD4, SMARCA4**, SMARCB1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1**
 
* One or more exons are not covered by sequencing for the indicated gene; see Additional Technical Information.
** Deletion/duplication detection is not available for this gene.
*** One or more exons are not covered by sequencing, and deletion/duplication detection is not available for this gene; see Additional Technical Information.
**** Deletion/duplication only; sequencing is not available for this gene.
Hotline History
View Hotline History
CPT Code(s)
81432; 81433; 81435; 81436; 81437; 81438
Components
Component Test Code*Component Chart NameLOINC
2012033Cancer Panel, Hereditary, Spcm31208-2
2012034Cancer Panel, Hereditary, Interp35474-6
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • Birt-Hogg-Dube (BHD) syndrome
  • Cowden syndrome
  • Familial Adenomatous Polyposis (FAP)
  • HBOC syndrome
  • Hereditary Diffuse Gastric Cancer (HDGC)
  • Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) syndrome
  • Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
  • Hereditary Papillary Renal Carcinoma (HPRC) syndrome
  • Hereditary Paraganglioma Pheochromocytoma
  • Juvenile Polyposis syndrome (JPS)
  • Li-Fraumeni syndrome (LFS)
  • Lynch syndrome
  • Malignant Mesothelioma
  • MUTYH-Associated Polyposis (MAP)
  • Peutz-Jegher syndrome (PJS)
  • PTEN Hamartoma Tumor syndrome
  • Rhabdoid Tumor Predisposition syndrome
  • Tuberous Sclerosis Complex (TSC)
  • Von Hippel Lindau (VHL) syndrome
  • Wilms Tumor